INCATE supports innovators
to fight drug-resistant bacterial infections
Our Mission
Supporting innovators to fight drug-resistant infections
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
Whats up?
Latest News
Unison Medicines is delighted to announce an oversubscribed first close of $500k of financing from a syndicate of highly sophisticated biopharma angels. Unison will use the proceeds to conduct a series of animal studies of [...]
We are happy to announce a new partnership with Granzer Regulatory Consulting & Services GmbH [...]
From bone flutes to synths, music has always been more than noise — it’s how [...]
The INCATE Selection Committee has chosen four new ventures for Stage I support. Meet the [...]
Did you know phages helped stop a cholera outbreak in Stalingrad during WWII? While antibiotics [...]
What we do
Supporting your venture
Advice
Advice from partners, including Industry, to enable; early alignment with medical needs and market demand, the development of a quality translational path and a plan to build a company.
Community
Access to a community of engaged individuals across industry, academia, entrepreneurs, policymakers, investors, public health and healthcare providers to share ideas and fight drug-resistant bacterial infections together.
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
